Bioverativ Therapeutics Inc.

225 2ND Ave, Waltham, Massachusetts, United States

Clinical Trials

44 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

81.0%

Phase 3

15.5%

Trial Status Distribution

Active, not recruiting

75.9%

Completed

20.7%

Terminated

1.7%

Withdrawn

1.7%

Clinical Trials

Trials sponsored by this organization (58)

A clinical study exploring the use of rFVIIIFc in patients with severe Haemophilia A who are undergoing Immune Tolerance Induction (ITI) for the first time

Phase 1

Active, not recruiting

Jul 2021

Safety, efficacy and PK of BIVV001 in pediatric patients with hemophilia A

Phase 1

Active, not recruiting

Jul 2021

A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, BIVV001, in Patients With Severe Hemophilia A (XTEND-1)

Phase 1

Active, not recruiting

Jun 2021164 participants

ong-term safety and efficacy of BIVV001 in Previously Treated Patients with hemophilia A

Phase 1

Active, not recruiting

May 202190 participants

Safety, efficacy and PK of BIVV001 in pediatric patients with hemophilia A

Phase 1

Active, not recruiting

May 202170 participants

ong-term safety and efficacy of BIVV001 in Previously Treated Patients with hemophilia A

Phase 1

Active, not recruiting

May 2021267 participants

ong-term safety and efficacy of BIVV001 in Previously Treated Patients with hemophilia A

Phase 1

Active, not recruiting

Apr 202190 participants

Open-Label with BIVV009 in patients with Cold Agglutinin Disease

Phase 1

Active, not recruiting

Jan 202124 participants

Page 1 of 8

Approvals

Approvals by Agency

FDA

Food and Drug Administration

Approvals

Recent Approvals

News

No news articles found

Back to Organizations